|
Post by johnhindepost on Aug 3, 2015 10:19:34 GMT -5
www.flashratings.com/stories/207539MannKind Corporation (MNKD) + Follow $4.25 -0.93% Aug 03, 10:56 AM EST MNKD "outperform", target reduced to $9 Aug 3, 2015 9:00 AM EDT RBC Capital Success rate3 August 3 (FlashRatings.com) - Analysts at RBC Capital maintain their "outperform" rating for MannKind Corporation (MNKD). The target price is reduced from $10 to $9. Tweet Share on StockTwits Latest ratings for MannKind Corporation (MNKD) Jefferies Success rate3 6/9/15 MNKD buy $9 "At the ADA meeting we spoke to 20 U.S. physicians who were familiar with Afrezza and found that while only six had prescribed the drug to..." view details.. Goldman Sachs Success rate3 5/12/15 MNKD sell $2 MLV & Co Success rate3 5/11/15 MNKD hold $4 Previous stories by RBC Capital for MannKind Corporation (MNKD) RBC Capital Success rate3 6/9/15 MNKD outperform $10 "SNY expected Afrezza to be a tier 3 benefit and the goal is to remove restrictions. It appears contract discussions with plans are..." view details.. RBC Capital Success rate3 2/4/15 MNKD outperform $13 "Afrezza wholesale acquisition cost varies from $226.06 to $278.59 for 360-600U which on a per unit basis comes down but still appears..." view details.. View all ratings for MannKind Corporation (MNKD)
|
|
|
Post by maytepper1 on Aug 6, 2015 5:42:19 GMT -5
|
|
|
Post by newmnkdinvestor on Aug 6, 2015 10:48:56 GMT -5
Surprised about the getting dropped by Sny comment. From someone else its to be expected.
|
|
|
Post by joeypotsandpans on Aug 6, 2015 10:55:44 GMT -5
Surprised about the getting dropped by Sny comment. From someone else its to be expected. Not if you've been following Josh for the last 18 mos. or so...he stated the $2 range before we shot to $11 last year...hmm, may be a harbinger of things to come if history repeats itself regarding timing
|
|
|
Post by newmnkdinvestor on Aug 6, 2015 11:31:37 GMT -5
I have not followed him and I just realized I mixed up two different analysts. I am a putz.
|
|
|
Post by nylefty on Aug 6, 2015 13:02:07 GMT -5
Notice the last sentence of the article:
With a return potential of 102.1%, the stock’s consensus target price stands at $8.47.
|
|
|
Post by BD on Aug 10, 2015 14:22:45 GMT -5
15:16 EDT MNKD theflyonthewall.com: MannKind may need to re-evaluate Afrezza strategy, says Piper Jaffray Piper Jaffray analyst Joshua Schimmer said in a post-earnings note on MannKind that he stills has concerns about the company's financial position and the trajectory for Afrezza, adding that he believes the company may need to re-evaluate its strategy if there is not an inflection of prescriptions for the inhaled insulin in the coming months. Schimmer maintains a Neutral rating on MannKind shares but raised his price target on the stock to $4 from $3.50 to reflect the lower spending evident in its Q2 report. :theflyonthewall.com
|
|
|
Post by maytepper1 on Aug 10, 2015 14:52:33 GMT -5
|
|
|
Post by mannmade on Aug 10, 2015 14:57:56 GMT -5
At this point neither here nor there for me. Seems like just another CYA note to stay relevant... They must not be reading user comments...
|
|
|
Post by maytepper1 on Aug 11, 2015 6:34:42 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 11, 2015 19:37:25 GMT -5
so i guess its about time lol
|
|
|
Post by brentie on Aug 13, 2015 13:50:17 GMT -5
|
|
|
Post by liane on Aug 13, 2015 14:01:18 GMT -5
brentie -
Like your latest incarnation!
|
|
|
Post by yossarian on Aug 13, 2015 14:02:48 GMT -5
No doubt Adam will come out with an article bashing it soon.
|
|
|
Post by mssciguy on Aug 13, 2015 14:05:59 GMT -5
No doubt Adam will come out with an article bashing it soon. It's like a Mexican birthday party, stab the pinata, get the candy. Dark side of the internet (excluding proboards) --- there is no editor.
|
|